PERIPHERAL ARTERY DISEASE (PAD)

Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon

Retrieved on: 
수요일, 3월 9, 2022
Health, Medical Devices, Technology, Other Technology, General Health, Clinical Trials, Cardiology, NASDAQ, Safety, Heart, Cytostasis, Clinical trial, Leg, CSI, Twitter, Medtronic, Annual report, DCB Bank, Private Securities Litigation Reform Act, Physician, Plaque, Peripheral artery disease, FDA, CV, DCB, IDE, LLC, Diabetes, Stent, Medical Affairs Bureau, Testosterone and the cardiovascular system, Form 10-K, Form 10-Q, Pain, News, Acquisition, Risk, Obesity, Hospital, Prevalence, PAD, Patient, Everolimus, Coronary artery disease, COO, SEC, Male, Organization, Amputation, Walking, View, Pharmaceutical industry, MD, SFA, Covidien, CVT, Cardiovascular Systems, Inc., Chansu Vascular Technologies, LLC, Peripheral Artery Disease (PAD), CARDIOVASCULAR SYSTEMS, INC., CHANSU VASCULAR TECHNOLOGIES, LLC, PERIPHERAL ARTERY DISEASE (PAD)

The peripheral DCB was used to successfully treat a 69 year-old male with a 7.5 cm lesion in his superficial femoral artery (SFA).

Key Points: 
  • The peripheral DCB was used to successfully treat a 69 year-old male with a 7.5 cm lesion in his superficial femoral artery (SFA).
  • We believe this promising new generation of everolimus DCBs could improve patient outcomes for those suffering from peripheral artery disease.
  • Jeffery Chambers, M.D., CSIs Chief Medical Officer, said, Following the announcement of the first in-human experience with CVTs coronary everolimus DCB in November 2021, we are thrilled to announce the first in-human experience with the peripheral everolimus DCB.
  • CVT was founded by Philippe Marco, MD, with the exclusive purpose to develop peripheral and coronary DCBs using everolimus.

Cardiovascular Systems, Inc. Reports Fiscal 2022 Second Quarter Financial Results

Retrieved on: 
목요일, 2월 3, 2022
Health, Cardiology, Other Health, Medical Devices, Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), Cardiovascular Systems, Inc., OrbusNeich, CORONARY ARTERY DISEASE (CAD), PERIPHERAL ARTERY DISEASE (PAD), CARDIOVASCULAR SYSTEMS, INC., ORBUSNEICH

CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart.

Key Points: 
  • CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart.
  • According to the Centers for Disease Control and Prevention, 18 million people in the United States have CAD, the most common form of heart disease.
  • With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.
  • See the instructions for use for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential adverse events.

Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery Diseases

Retrieved on: 
목요일, 1월 13, 2022
Health, Medical Devices, Cardiology, Calendar, CSI, Fracture, Patient, Technology, PCI, News, Moyamoya disease, Annual report, Man, Lithotripsy, Korea Disease Control and Prevention Agency, Kidney, Center, Clinical trial, Private Securities Litigation Reform Act, CAD, SEC, Form 10-K, Plaque, Organization, Degenerative disease, Population, Knee, NASDAQ, Coronary artery disease, Death, CEO, IVL, Leg, Atherosclerosis, Obesity, Artery, View, Form 10-Q, Pain, Program, Heart, Diabetes, PAD, MACE, Testosterone and the cardiovascular system, Risk, Calcium, Walking, Amputation, Twitter, FDA, Cardiovascular disease, Prevalence, Hospital, Physician, Woman, Pharmaceutical industry, Medical imaging, Cardiovascular Systems, Inc., Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), CARDIOVASCULAR SYSTEMS, INC., CORONARY ARTERY DISEASE (CAD), PERIPHERAL ARTERY DISEASE (PAD)

Lithotripsy has been used successfully for many years in the treatment of kidney and gall stones, and more recently has found application in treatment of calcified coronary and peripheral arteries.

Key Points: 
  • Lithotripsy has been used successfully for many years in the treatment of kidney and gall stones, and more recently has found application in treatment of calcified coronary and peripheral arteries.
  • The CSI IVL systems are designed to improve upon the limitations of incumbent technology, allowing physicians to cross and treat more challenging atherosclerotic lesions.
  • In coronary, CSIs current product offering, which is focused on the treatment of severely calcified coronary arteries using orbital atherectomy, targets 12% of percutaneous coronary interventions (PCI).
  • CSI is a registered trademark of Cardiovascular Systems, Inc. All other trademarks cited herein are owned by their respective owners.

Cardiovascular Systems, Inc. Reports Fiscal 2022 First Quarter Financial Results

Retrieved on: 
화요일, 11월 9, 2021
Health, Medical Devices, Surgery, Other Health, General Health, Cardiology, Biotechnology, Peripheral Artery Disease (PAD), Coronary Artery Disease (CAD), Cardiovascular Systems, Inc., PERIPHERAL ARTERY DISEASE (PAD), CORONARY ARTERY DISEASE (CAD), CARDIOVASCULAR SYSTEMS, INC.

With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.

Key Points: 
  • With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.
  • CAD is a life-threatening condition and a leading cause of death in men and women globally.
  • CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart.
  • The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow.

Cardiovascular Systems, Inc. Announces First Patient Treated with ViperCross™ Peripheral Support Catheter

Retrieved on: 
수요일, 9월 29, 2021
Medical Devices, Health, Surgery, Research, Cardiology, Science, Diamondback, News, Leg, Moyamoya disease, Annual report, Walking, Risk, Calcium, Coronary artery disease, Plaque, Sale, Private Securities Litigation Reform Act, NASDAQ, Testosterone and the cardiovascular system, FDA, USA, Patient, Catheter, CSI, Atherectomy, Physician, PVI, MD, Stent, Hospital, Heart, Form 10-K, PAD, Diabetes, Twitter, Pain, Prevalence, Contraindication, Anatomy, Peripheral artery disease, Obesity, Fracture, Â, Stealth, Organization, Amputation, SEC, Form 10-Q, Pharmaceutical industry, Medical device, Medical imaging, Cardiovascular Systems, Inc., Peripheral Artery Disease (PAD), CARDIOVASCULAR SYSTEMS, INC., PERIPHERAL ARTERY DISEASE (PAD)

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient has been successfully treated with its ViperCross peripheral support catheter.

Key Points: 
  • Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient has been successfully treated with its ViperCross peripheral support catheter.
  • Dr. Billy J. Kim, MD, The Surgical Clinic, Nashville, Tenn., treated the first patient with ViperCross.
  • Peripheral support catheters are used during peripheral vascular intervention (PVI) procedures for guidewire support to enable lesion crossing, as well as for guidewire exchanges.
  • The 014 ViperCross support catheters are intended to be used to access discrete regions of the peripheral and/or coronary vasculature.

Cardiovascular Systems, Inc. Reports Fiscal 2021 Fourth Quarter and Full Year Financial Results

Retrieved on: 
수요일, 8월 4, 2021
Health, Surgery, Cardiology, Medical Devices, Clinical medicine, Health, Medicine, Cardiovascular diseases, Amphetamine, Bariatrics, Body shape, Nutrition, Obesity, Diabetes, Peripheral Artery Disease (PAD), Coronary Artery Disease (CAD), Cardiovascular Systems, Inc., PERIPHERAL ARTERY DISEASE (PAD), CORONARY ARTERY DISEASE (CAD), CARDIOVASCULAR SYSTEMS, INC.

With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.

Key Points: 
  • With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.
  • Stents are prone to fractures and high recurrence rates, and treatment of hard, calcified lesions often leads to vessel damage and suboptimal results.
  • CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart.
  • See the instructions for use for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential adverse events.

Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon Catheters

Retrieved on: 
화요일, 6월 1, 2021
Health, Medical devices, Cardiology, Manufactured goods, Catheters, Interventional radiology, Goods economics), Balloon catheter, Stent, Balloon, Toy balloon, Peripheral Artery Disease (PAD), Cardiovascular Systems, Inc., OrbusNeich, PERIPHERAL ARTERY DISEASE (PAD), CARDIOVASCULAR SYSTEMS, INC., ORBUSNEICH

JADE is an OTW balloon catheter for PTA in the peripheral vasculature, including obstructed native arteries and synthetic arteriovenous dialysis fistulae, as well as for post-dilatation of balloon expandable and self-expanding stents.

Key Points: 
  • JADE is an OTW balloon catheter for PTA in the peripheral vasculature, including obstructed native arteries and synthetic arteriovenous dialysis fistulae, as well as for post-dilatation of balloon expandable and self-expanding stents.
  • JADE is a non-compliant balloon designed for high pressure tolerance and balloon dilatation with even pressure distribution for the treatment of complex lesions.
  • The predictable, uniform inflation of these non-compliant balloons allows for accuracy in balloon sizing and reduces the potential for vessel recoil.
  • Said Dr. Rao, The deliverability of the JADE balloons, whether it be on the 0.014, 0.018 or 0.035 platform, is exceptional.

Cardiovascular Systems, Inc. Reports Fiscal 2021 Third-Quarter Financial Results

Retrieved on: 
목요일, 5월 6, 2021
Health, Surgery, Cardiology, Medical devices, Interventional radiology, Medical specialties, Medicine, Clinical medicine, Medical devices, Angioplasty, Stent, Artery, Peripheral Artery Disease (PAD), Coronary Artery Disease (CAD), Cardiovascular Systems, Inc., PERIPHERAL ARTERY DISEASE (PAD), CORONARY ARTERY DISEASE (CAD), CARDIOVASCULAR SYSTEMS, INC.

Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation.

Key Points: 
  • Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation.
  • These systems use a diamond-coated crown, attached to an orbiting shaft, which sands away plaque while preserving healthy vessel tissue \xe2\x80\x94 a critical factor in preventing reoccurrences.
  • Balloon angioplasty and stents have significant shortcomings in treating hard, calcified lesions.
  • CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart.

Journal of Medical Economics Article Demonstrates Economic Benefits of Cardiovascular Systems Orbital Atherectomy in the Treatment of Peripheral Artery Disease (PAD)

Retrieved on: 
월요일, 5월 3, 2021
General Health, Medical devices, Infectious diseases, Health, Cardiology, XC2, Catheter, Peripheral Artery Disease (PAD), Cardiovascular Systems, Inc., LIBERTY 360°, PERIPHERAL ARTERY DISEASE (PAD), CARDIOVASCULAR SYSTEMS, INC., LIBERTY 360°

CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this release.

Key Points: 
  • CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this release.
  • Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation.
  • The company\xe2\x80\x99s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
  • The Stealth 360\xc2\xae PAD System is CE Marked.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210503005494/en/\n"